Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

– Results Reflect Continued Financial Strength and Deleveraging –

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

PRAGUE, July 9, 2025 /PRNewswire/ -- Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of...

- A word from our sponsors -

HomeTagsBiosimilar

Tencent Cloud Unveils New AI Agents, WorkBuddy and Miora, Driving Innovation and Real Business Outcomes Across Southeast Asia

CDP Announces Transformative Investment to Accelerate Environmental Transparency Worldwide

Vietnam-aligned OceanLotus pivots to spy on domestic targets as it takes a more selective approach abroad, ESET Research finds

Tag: biosimilar

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us